SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

05 May 2022 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma

19 Apr 2022 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

24 Feb 2022 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

01 Feb 2022 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma

10 Dec 2021 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

06 Dec 2021 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas

29 Nov 2021 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

23 Nov 2021 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

04 Nov 2021 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma

27 Oct 2021 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics

20 Oct 2021 03:45:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors

20 Oct 2021 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

07 Sep 2021 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

30 Aug 2021 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

04 Aug 2021 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

03 Aug 2021 06:00:01 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations

03 Aug 2021 03:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer

27 Jul 2021 05:00:01 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041

20 Jul 2021 04:30:00 By Nasdaq GlobeNewswire